SCHEMBL21663151

SCHEMBL21663151

Cc1nc2c(n1C1CC1)C(=O)/C(=C/N(C)C)C2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 3/20 0.36
▸ CYP2C9 P11712 3/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ CYP2C19 P33261 2/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ STAT3 P40763 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.34
▸ HSD17B10 Q99714 3/20 0.33
▸ CASP1 P29466 2/20 0.33
▸ CASP7 P55210 2/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ ALOX15 P16050 2/20 0.33
▸ GAA P10253 1/20 0.33
▸ CLK4 Q9HAZ1 1/20 0.32
▸ LMNA P02545 1/20 0.31
▸ MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21662993 0.79 PDE5A (0.34) MEN1KMT2AKDM4E
SCHEMBL21663311 0.77 KDM4E (0.34) MEN1KMT2AKDM4ESMARCA4
SCHEMBL21663204 0.77 CYP1A2 (0.38) CYP1A2MEN1KMT2ACYP2C19CYP3A4
SCHEMBL21663307 0.73 KDM4E (0.33) MEN1KMT2AKDM4E
SCHEMBL21663300 0.71 ADORA2A (0.38) CYP2C9MEN1KMT2ACYP2C19KDM4E
SCHEMBL21663173 0.70 KDM4E (0.31) MEN1KMT2AKDM4ECREBBPBRD4
SCHEMBL21663156 0.68 KDM4E (0.33) MEN1KMT2AKDM4E
SCHEMBL21663150 0.67 ALDH1A1 (0.39) CYP1A2CYP2C9MEN1KMT2AALDH1A1
SCHEMBL22612601 0.65 ALDH1A1 (0.40) CYP1A2CYP2C9MEN1KMT2AALDH1A1
SCHEMBL21663303 0.62 ALDH1A1 (0.47) CYP1A2CYP2C9MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11168088-B2 Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. 2021-11-09 — — US disclosed
US-20200039983-A1 PYRIDYLAMINO SUBSTITUTED HETEROTRICYCLIC COMPOUNDS, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2020-02-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11168088-B2 Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof CYP2D6, PNPO, CYP2B6 CYP1A2 39/4885CYP2C9 8/4885MEN1 728/4885
US-20200039983-A1 PYRIDYLAMINO SUBSTITUTED HETEROTRICYCLIC COMPOUNDS, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF CYP2D6, PNPO, CYP2B6 CYP1A2 39/4885CYP2C9 8/4885MEN1 728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback